BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...also seeking to create an innovative pipeline of its own. The round also included contributions from Panacea Venture...
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

...in a series C round led by Panacea Venture...
...Johnson Development Corp, WuXi AppTec, WI Harper, Panacea Venture...
BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...Inc. (formerly XW Laboratories Inc.) raised $40 million in a series C round led by Panacea Venture...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...raised $34 million in a series A led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture...
BioCentury | Jul 30, 2019
Financial News

June 30 Financial Quick Takes: $40M series B for Hinova; plus TriArm and PredictImmune raise rounds

...cancer, TriArm Therapeutics (Shanghai, China) raised $20 million in a series A round led by Panacea Venture...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

...$50 million Investors: Lee’s Pharmaceutical International Ltd., Wealthy Chance Fortune Ltd., Coyote Investment Pte. Ltd., Panacea Venture...
BioCentury | Jun 10, 2019
Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

...NYSE:LLY), where she focused on drug and biomarker discovery. A group of new investors, including Panacea Venture...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

...Cancer Cash" ). Panacea's USD fund closes at $180.5M Panacea Venture closed its oversubscribed $180.5 million Panacea Venture...
...with a $50 million series A round to develop ophthalmic drugs. Coyote Investment Pte. Ltd., Panacea Venture...
...Oncology Ayala Pharmaceuticals Inc. Galectin Therapeutics Inc. Genmab A/S Lee's Pharmaceutical Holdings Ltd. New Horizon Health Technology Co. Ltd. Oxford BioMedica plc Panacea Venture China...
BioCentury | Dec 7, 2018
Financial News

Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Dec. 3 it raised $18 million in the first tranche of a $35 million series A round led by Chinese VC firm Panacea Ventures. VI Ventures...
BioCentury | Dec 3, 2018
Financial News

Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Monday it raised $35 million in a tranched series A round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated. Tactiva...
Items per page:
1 - 10 of 13
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...also seeking to create an innovative pipeline of its own. The round also included contributions from Panacea Venture...
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

...in a series C round led by Panacea Venture...
...Johnson Development Corp, WuXi AppTec, WI Harper, Panacea Venture...
BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...Inc. (formerly XW Laboratories Inc.) raised $40 million in a series C round led by Panacea Venture...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...raised $34 million in a series A led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture...
BioCentury | Jul 30, 2019
Financial News

June 30 Financial Quick Takes: $40M series B for Hinova; plus TriArm and PredictImmune raise rounds

...cancer, TriArm Therapeutics (Shanghai, China) raised $20 million in a series A round led by Panacea Venture...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

...$50 million Investors: Lee’s Pharmaceutical International Ltd., Wealthy Chance Fortune Ltd., Coyote Investment Pte. Ltd., Panacea Venture...
BioCentury | Jun 10, 2019
Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

...NYSE:LLY), where she focused on drug and biomarker discovery. A group of new investors, including Panacea Venture...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

...Cancer Cash" ). Panacea's USD fund closes at $180.5M Panacea Venture closed its oversubscribed $180.5 million Panacea Venture...
...with a $50 million series A round to develop ophthalmic drugs. Coyote Investment Pte. Ltd., Panacea Venture...
...Oncology Ayala Pharmaceuticals Inc. Galectin Therapeutics Inc. Genmab A/S Lee's Pharmaceutical Holdings Ltd. New Horizon Health Technology Co. Ltd. Oxford BioMedica plc Panacea Venture China...
BioCentury | Dec 7, 2018
Financial News

Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Dec. 3 it raised $18 million in the first tranche of a $35 million series A round led by Chinese VC firm Panacea Ventures. VI Ventures...
BioCentury | Dec 3, 2018
Financial News

Panacea backs Tactiva in $35M series A

Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Monday it raised $35 million in a tranched series A round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated. Tactiva...
Items per page:
1 - 10 of 13